Regenicin Financial Statements From 2010 to 2025
| RGIN Stock | USD 0.0001 0.00 0.00% |
Check Regenicin financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenicin's main balance sheet or income statement drivers, such as , as well as many indicators such as . Regenicin financial statements analysis is a perfect complement when working with Regenicin Valuation or Volatility modules.
Regenicin |
Regenicin Company Return On Asset Analysis
Regenicin's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Regenicin Return On Asset | -37.38 |
Most of Regenicin's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenicin is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Regenicin has a Return On Asset of -37.3831. This is 327.24% higher than that of the Healthcare sector and 58.4% higher than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.
Regenicin Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Regenicin's current stock value. Our valuation model uses many indicators to compare Regenicin value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regenicin competition to find correlations between indicators driving Regenicin's intrinsic value. More Info.Regenicin is rated third in return on asset category among its peers. It also is rated third in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Regenicin by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regenicin's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Regenicin Financial Statements
Regenicin investors utilize fundamental indicators, such as revenue or net income, to predict how Regenicin Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.